Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper

Cancer Research

Volumn 62, Issue 22, 2002, Pages 6559-6565

  Katano, Kuniyuki ^a   Kondo, Akira ^a   Safaei, Roohangiz ^a   Holzer, Alison ^a   Samimi, Goli ^a   Mishima, Misako ^a   Kuo, Yien Ming ^c   Rochdi, Myriam ^b   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b SkyePharma Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CARRIER PROTEIN; CHAPERONE; CISPLATIN; COPPER ION; DNA; MENKES PROTEIN; PLATINUM; PROTEIN HAH1; UNCLASSIFIED DRUG; WILSON DISEASE PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; ION CURRENT; ION TRANSPORT; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; CATION TRANSPORT PROTEINS; CISPLATIN; COPPER; COPPER SULFATE; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; HOMEOSTASIS; HUMANS; MEMBRANE PROTEINS; MOLECULAR CHAPERONES; MUTATION; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0037112421     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Schabel, F. M., Jr., Skipper, H. E., and Trader, M. W. Concepts for controlling drug-resistant tumor cells. In: H. T. Mouridsen and T. Palshof (eds.), Breast Cancer: Experimental and Clinical Aspects, pp. 199-212. Oxford: Pergamon Press, 1980
2. Inoue, K., Mukaiyama, T., Mitsui, I., and Ogawa, M. In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay. Cancer Chemother. Pharmacol., 15: 208-213, 1985
3. Wilson, A. P., Ford, C. H., Newman, C. E., and Howell, A. Cisplatin and ovarian carcinoma. In vitro chemosensitivity of cultured tumor cells from patients receiving high dose cisplatin as first line treatment. Br. J. Cancer, 56: 763-773, 1987
4. Andrews, P. A., Jones, J. A., Varki, N. M., and Howell, S. B. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun., 2: 93-100, 1990
5. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35-43, 1990
6. Perez, R. P., Hamilton, T. C., Ozols, R. F., and Young, R. C. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer (Phila.), 71: 1571-1580, 1993
7. Fink, D., Aebi, S., and Howell, S. B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res., 4: 1-5, 1998
8. Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F., and Hamilton, T. C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res., 57: 850-856, 1997
9. Gately, D. P., and Howell, S. B. Cellular accumulation of the anticancer agent cisplatin: A review. Br. J. Cancer, 67: 1171-1176, 1993
10. Waud, W. R. Differential uptake of cis-diamminedichloro-platinum(II) in sensitive and resistant murine L1210 leukemia cell lines. Cancer Res., 46: 6549-6555, 1987
11. Teicher, B. A., Holden, S. A., Herman, T. S., Sotomayor, E. A., Khandekar, V., Rosbe, K. W., Brann, T. W., Korbut, T. T., and Frei, E., III. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II) Int. J. Cancer, 47: 252-260, 1991
12. Metcalfe, S. A., Cain, K., and Hill, B. T. Possible mechanisms for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett., 31: 163-169, 1986
13. Oldenburg, J., Begg, A. C., van Vugt, M. J. H., Ruevekamp, M., Schornagel, J. H., Pinedo, H. M., and Los, G. Characterization of resistance mechanisms to cis-diamminedichloroplatinum (II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res., 54: 487-493, 1994
14. Wallner, K. E., DeGregorio, M. W., and Li, G. C. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res., 46: 6242-6245, 1986
15. Twentyman, P. R., Wright, K. A., Mistry, P., Kelland, L. R., and Murrer, B. A. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res., 52: 5674-5680, 1992
16. Kelland, L. R., Mistry, P., Abel, G., Freidlos, F., Loh, S. Y., Roberts, J. J., and Harrap, K. R. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res., 52: 1710-1716, 1992
17. Andrews, P. A., and Albright, K. D. Role of membrane ion transport in cisplatin accumulation. In: S. B. Howell (ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, pp. 151-159. New York: Plenum Press, 1991
18. Andrews, P. A., Mann, S. C., Huynh, H. H., and Albright, K. D. Role of the Na+, K+-ATPase in the accumulation of cis-diammine-dichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res., 51: 3677-3681, 1991
19. Andrews, P. A., Velury, S., Mann, S. C., and Howell, S. B. cis-diamminedichloro-platinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 48: 68-73, 1988
20. Mann, S. C., Andrews, P. A., and Howell, S. B. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int. J. Cancer, 48: 866-872, 1991
21. Mann, S. C., Andrews, P. A., and Howell, S. B. Short-term cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 25: 236-240, 1990
22. Chau, Q., and Stewart, D. J. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant. Cancer Chemother. Pharmacol., 44: 193-202, 1999
23. Parker, R. J., Eastman, A., Bostick-Bruton, F., and Reed, E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Investig., 87: 772-777, 1991
24. Ishikawa, T., and Ali-Osman, F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem., 268: 20116-20125, 1993
25. Ishikawa T., Wright, C. D., and Ishizuka, H. GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J. Biol. Chem., 269: 29085-29093, 1994
26. Safaei, R., and Howell, S. B. Cross-resistance between cisplatin, carboplatin, copper, and arsenite in human tumor cell lines. Proc. Am. Assoc. Cancer Res., 42: 424, 2001
27. Safaei, R., Katano, K., Samimi, G., Naerdemann, W., and Howell, S. B. Cisplatin resistance is mediated by copper homeostasis mechanisms. Proc. Am. Assoc. Cancer Res., 34: 423, 2002
28. La Fontaine, S. L., Firth, S. D., Camakaris, J., Englezou, A., Theophilos, M. B., Petris, M. J., Howie, M., Lockhart, P. J., Greenough, M., Brooks, H., Reddel, R. R., and Mercer, J. F. Correction of the copper transport defect of Menkes patient fibroblasts by expression of the Menkes and Wilson ATPases. J. Biol. Chem., 273: 31375-31380, 1998
29. Sarkar, B. Copper transport and its defect in Wilson disease: Characterization of the copper-binding domain of Wilson disease ATPase. J. Inorg. Biochem., 79: 187-191, 2000
30. Pena, M. M., Lee, J., and Thiele, D. J. A delicate balance: Homeostatic control of copper uptake and distribution. J. Nutr., 129: 1251-1260, 1999
31. Zhou, B., and Gitschier, J. hCTR1: A human gene for copper uptake identified by complementation in yeast. Proc. Natl. Acad. Sci. USA, 94: 7481-7486, 1997
32. Moller, L. B., Petersen, C., Lund, C., and Horn, N. Characterization of the hCTR1 gene: Genomic organization, functional expression, and identification of a highly homologous processed gene. Gene (Amst.), 257: 13-22, 2000
33. Amaravadi, R., Glerum, D. M., and Tzagoloff, A. Isolation of a cDNA encoding the human homolog of COX17, a yeast gene essential for mitochondrial copper recruitment. Hum. Genet., 99: 329-333, 1997
34. Culotta, V. C., Klomp, L. W., Strain, J., Casareno, R. L., Krems, B., and Gitlin, J. D. The copper chaperone for superoxide dismutase. J. Biol. Chem., 272: 23469-23472, 1997
35. Klomp, L. W., Lin, S. J., Yuan, D. S., Klausner, R. D., Culotta, V. C., and Gitlin, J. D. Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. J. Biol. Chem., 272: 9221-9226, 1997
36. Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z-S., Terada, K., Furukawa, T., Yang, X-L., Gao, H., Miura, N., Sugiyama, T., and Akiyama, S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res., 60: 1312-1316, 2000
37. Katano, K., Safaei, R., Samimi, G., Naerdemann, W., Holzer, A., and Howell, S. B. Copper-transport P-type adenosine triphosphatase (ATP7B) modifies cisplatin resistance of carcinoma cells. Proc. Am. Assoc. Cancer Res., 43: 423, 2002
38. Nicholson, D. L., Purser, S. M., and Maier, R. H. Differential cytotoxicity of trace metals in cisplatin-sensitive and -resistant human ovarian cancer cells. Biometals, 11: 259-263, 1998
39. Mishima, M., Samimi, G., Kondo, A., Lin, X., and Howell, S. B. The cellular pharmacology of oxaliplatin resistance. Eur. J. Cancer, 38: 1405-1412, 2002
40. Lippard, S. J. Free copper ions in the cell [see comments]? Science (Wash. DC), 284: 748-749, 1999
41. Linder, M. C., and Hazegh-Azam, M. Copper biochemistry and molecular biology. Am. J. Clin. Nutr., 63: 797S-811S, 1996
42. O’Halloran, T. V., and Culotta, V. C. Metallochaperones, an intracellular shuttle service for metal ions. J. Biol. Chem., 275: 25057-25060, 2000
43. Camakaris, J., Voskoboinik, I., and Mercer, J. F. Molecular mechanisms of copper homeostasis. Biochem. Biophys. Res. Commun., 261: 225-232, 1999
44. Rae, T. D., Schmidt, P. J., Pufahl, R. A., Culotta, V. C., and O’Halloran, T. V. Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase [see comments]. Science (Wash. DC), 284: 805-808, 1999
45. Hamza, I., Schaefer, M., Klomp, L. W., and Gitlin, J. D. Interaction of the copper chaperone HAH1 with the Wilson disease protein is essential for copper homeostasis. Proc. Natl. Acad. Sci. USA, 96: 13363-13368, 1999
46. Pufahl, R. A., Singer, C. P., Peariso, K. L., Lin, S. J., Schmidt, P. J., Fahmi, C. J., Culotta, V. C., Penner-Hahn, J. E., and O’Halloran, T. V. Metal ion chaperone function of the soluble Cu(I) receptor Atx1 [see comments]. Science (Wash. DC), 278: 853-856, 1997